| Literature DB >> 27134708 |
Ramesh M Kumar1, Michael Finn1.
Abstract
Gliosarcoma (GS) is a rare and exceedingly malignant neoplasm of the central nervous system. It displays clinical features similar to glioblastoma, yet is histologically unique as it harbors both gliomatous and sarcomatous cellular components. Involvement of the neuro-axis is predominantly limited to the cerebral parenchyma and meninges. Primary GS of the spinal cord is rarely encountered. We report a case of a 54 year old male who presented with 2 months of progressive, bilateral lower extremity sensory deficits. Magnetic resonance imaging of the neuro-axis revealed multiple intradural lesions involving the cervical and thoracic spinal cord without evidence of intracranial involvement. Surgical resection of a dural based, extramedullary cervical lesion and two exophytic, intramedullary thoracic lesions revealed gliosarcoma, WHO grade IV. The patient died approximately 11 months after presentation. This report confirms that GS is not limited to supratentorial involvement and can primarily affect the spinal cord.Entities:
Keywords: Spine; gliosarcoma; spinal tumor; surgical resection
Year: 2016 PMID: 27134708 PMCID: PMC4827645 DOI: 10.4081/rt.2016.6102
Source DB: PubMed Journal: Rare Tumors ISSN: 2036-3605
Figure 1.Sagittal thoracic (A), axial cervical (B) and saggital cervical (C) planes of T1 weighted magnetic resonance images showing multiple contrast enhancing, intradural, extra-medullary lesions.
Figure 2.Sagittal T1 weight magnetic resonance images of the lumbar spine showing a single, contrast-enhancing lesion at the level of the L1 vertebral body.
Figure 3.A) Photomicrograph showing the two components in the gliosarcoma: cytologically atypical nests of glial cells (arrows) are intimately admixed with spindled sarcomatous tumor (Hematoxylin and Eosin, 200×). B) Reticulin stain better differentiates the reticulin poor nests of malignant glial cells (arrows) from the reticulin-rich sarcomatous component (modified Gordon and Sweets reticulum II stain [Ventana Corp, Tuscon, AZ], 200×). C) Immunostaining for GFAP shows strong immunoreactivity in the malignant glial component (arrows), with only occasional entrapped immunoreactive cells within the spindled sarcomatous component (Immunostaining for GFAP [Dako Corp., Carpinteria, CA], with light hematoxylin counterstain, 200×). D) Elevated MIB-1 cell cycle labeling in both the malignant glial and sarcomatous (arrow) components (200×).